Imaging Test May Halve Prostate Biopsies After MRI

A new imaging test showing promise in identifying prostate cancer cells could significantly reduce the number of men undergoing unnecessary biopsies, according to research presented at the European Association of Urology Congress in London. The test, utilizing a scan that highlights cancerous tissue, offers a potential pathway to more targeted diagnosis and treatment for suspected prostate cancer, minimizing invasive procedures for those who don’t require them.

How the Scan Works: PSMA PET/CT and Targeted Biopsies

The research centers around a scan called prostate-specific membrane antigen (PSMA) radioligand PET/CT. PSMA is a protein found on the surface of prostate cancer cells. The scan uses a radioactive tracer that binds to this protein, making cancerous areas “glow” during imaging. This allows doctors to pinpoint the location of potentially significant tumors with greater accuracy than traditional methods. The PRIMARY2 trial, a multicentre, phase 3, randomised controlled trial, is investigating how this scan can refine the diagnostic process. The trial is registered on ClinicalTrials.gov as NCT05154162.

Currently, many men with suspected prostate cancer, identified through elevated prostate-specific antigen (PSA) levels or during initial MRI scans, undergo transperineal prostate biopsies – a procedure where tissue samples are taken from the prostate gland. These biopsies can be uncomfortable, carry risks of infection, and sometimes detect insignificant cancers that would never have caused harm. The PRIMARY2 trial aims to determine if adding the PSMA PET/CT scan before a biopsy can help identify men who can safely avoid the procedure altogether, or at least have a more targeted biopsy focusing on areas of concern.

The PRIMARY2 Trial: Design and Participants

The PRIMARY2 trial involves 660 participants scheduled to undergo biopsy for suspected prostate cancer. Participants are eligible if they have a Prostate Imaging-Reporting and Data System (PI-RADS) score of 2 and “red flags” on their MRI, or a PI-RADS score of 3. PI-RADS is a standardized system for reporting MRI findings, with higher scores indicating a greater likelihood of significant cancer. Participants are randomly assigned to either undergo the PSMA PET/CT scan before biopsy (the experimental arm) or proceed directly to a template transperineal prostate biopsy (the control arm).

In the experimental arm, if the PSMA PET/CT scan is positive, participants undergo a targeted biopsy, focusing on the areas identified by the scan. If the scan is negative, they are monitored with regular PSA tests instead of having a biopsy. The study, detailed in a protocol published in PubMed, will follow participants for up to two years after randomization to assess the long-term impact of this approach.

What Does This Mean for Prostate Cancer Diagnosis?

The potential benefit of this approach is twofold. First, it could reduce the number of unnecessary biopsies performed, sparing many men from the discomfort, anxiety, and potential complications associated with the procedure. Second, for those who do require a biopsy, the PSMA PET/CT scan can help guide the biopsy to the most suspicious areas, increasing the chances of detecting significant cancer and improving treatment planning. The study aims to demonstrate that the addition of the PSMA scan will allow some men to avoid biopsy without missing significant prostate cancer, and will facilitate biopsy targeting of PSMA-avid sites.

However, it’s crucial to understand that this research is still ongoing. The PRIMARY2 trial is designed to determine whether this approach is safe and effective, and the results are not yet available. The primary endpoint of the trial is the detection of Gleason score 3 + 4 (≥10%) = 7 disease (grade group 2) or higher on transperineal prostate biopsy. So the study is focused on identifying cancers that are considered clinically significant and require treatment.

Understanding the Limitations and Nuances

It’s vital to note that the PSMA PET/CT scan is not a perfect test. Like all medical tests, it can have false positives (identifying cancer when none is present) and false negatives (missing cancer that is present). The PRIMARY2 trial is designed to evaluate the impact of these potential errors on patient outcomes. The study population is specifically selected – men with inconclusive or suspicious MRI findings. The scan may not be appropriate for all men with suspected prostate cancer.

The trial likewise focuses on transperineal biopsies, a specific type of biopsy approach. The results may not be directly applicable to other biopsy techniques. The study’s findings will need to be carefully considered in the context of individual patient characteristics, and preferences.

The Broader Context of Prostate Cancer Screening and Diagnosis

Prostate cancer is the most common cancer in men in many countries. Early detection is often key to successful treatment, but screening for prostate cancer remains a complex issue. The apply of PSA testing as a screening tool is controversial, as it can lead to overdiagnosis and overtreatment of slow-growing cancers that may never cause harm. Multiparametric magnetic resonance imaging (mpMRI) has become increasingly important in evaluating men with elevated PSA levels or other risk factors for prostate cancer. The PRIMARY2 trial builds on this foundation by exploring how PSMA PET/CT can further refine the diagnostic process.

A related publication, noted in PubMed, highlights the ongoing clinical trial protocol for PRIMARY2, emphasizing its phase 3, randomised controlled trial design.

What Comes Next: Trial Completion and Potential Guidance Updates

The PRIMARY2 trial is currently recruiting participants and is expected to be completed in the coming years. Once the results are available, they will be carefully analyzed and presented to regulatory authorities and medical organizations. If the trial demonstrates that the PSMA PET/CT scan improves diagnostic accuracy and reduces unnecessary biopsies, it could lead to changes in clinical guidelines for prostate cancer diagnosis and management.

The European Association of Urology (EAU) and other professional societies will likely review the trial findings and update their recommendations accordingly. It’s also possible that the scan could become more widely available as a diagnostic tool, potentially improving the care of men with suspected prostate cancer. For now, men with concerns about prostate cancer should discuss their individual risk factors and screening options with a qualified healthcare professional.